Does the Inhibition of Valosin Containing Protein (VCP) Has an Effect on Apoptosis of Bone Marrow Mesenchymal Stem Cells Derived from Acute Lymphoblastic Leukemia Patients and Healthy Donors?

Proceedings

Nakkaş, Hilal¹  Çaylı, Sevil²  Kipel, Şeyma³  Köksal, Yasin⁴ 

[1] Ankara Child Health and Disease Hematology Oncology Training and Research Hospital, 06080 Ankara, Turkey;Author to whom correspondence should be addressed.;Department of Histology and Embryology, Ankara Yıldırım Beyazıt University, 06800 Ankara, Turkey;Presented at the 2nd International Cell Death Research Congress, Ä°zmir, Turkey, 1–4 of November 2018

关键词: Acute lymphoblastic leukemia (ALL);    Mesenchymal stem cells (MSCs);    apoptosis;    DBeQ;    p97/VCP;   

DOI  :  10.3390/proceedings2251576

学科分类：社会科学、人文和艺术（综合）

来源: mdpi

【 摘 要 】

Acute lymphoblastic leukemia (ALL) is the most common cancer type observed in childhood. Bone marrow (BM) microenvironment has significant role both at the beginning and the progress of leukemic period. Mesenchymal stem cells (MSCs) that make up microenvironment, regulate growth factors, cytokines and induction of survival of ALL cells by generating intracellular signals and establishing drug resistance. p97/VCP is a type of protein and it is responsible for also intracellular ubiquitin proteasome pathway, endoplasmic-reticulum-associated protein degradation, cell cycle, apoptosis and autophagy. It is shown that p97/VCP is overexpressed in the most of the cancer types including the ALL. p97/VCP inhibitors serve as therapeutic agents. Amongst p97/VCP inhibitors, DBeQ (dibenzylquinazoline-2,4-diamine) provide to undergo apoptosis and prevents cell proliferation. In this study, MSCs obtained from ALL patients and healthy donors were isolated by density-gradient method and then these cells were cultured. Cells were incubated with DBeQ. Cell apoptosis was determined by Annexin V/PI method (in flow cytometry). According to obtained data, availability of p97/VCP inhibitor which was recommended to be used as therapeutic agent in the treatment of other cancer types, in ALL treatment will be evaluated and this study will provide a basis for future studies.

【 授权许可】

CC BY